Dawn Rogers - Pfizer President

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  President
Mr. Dawn Rogers is Chief Human Resources Officer, Executive Vice President since January 2019. He was as Executive Vice President, Worldwide Human Resources from June 2018 until December 2018. Senior Vice President, Human Resources for the Chief Operating Officer from November 2017 until May 2018. Senior Vice President of Human Resources for Pfizer Essential Health, Global Product Development, and the Legal and Compliance Divisions from 2016 until November 2017. Senior Vice President of Human Resources for the Global Innovative Pharma Business from 2013 until 2016. Senior Vice President of Human Resources for the Primary Care Business Unit from 2011 until 2013. Senior Vice President of Human Resources for Worldwide Research and Development from 2008 until 2011. Vice President of Human Resources for Pfizer European Commercial Operations from 2006 to 2008.
Age: 54  President Since 2019      
212 733-2323  www.pfizer.com

Dawn Rogers Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 5.78 % which means that on every $100 spent on asset it made $5.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 25.41 %, implying that it generated $25.41 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 8.28. Pfizer Current Assets are expected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 32.8 Billion. The current year Tax Assets is expected to grow to about 6.1 B, whereas Goodwill and Intangible Assets are expected to decline to about 89.2 B. Pfizer Tax Liabilities is expected to decrease significantly based on the last few years of reporting. The past year's Tax Liabilities was at 18.68 Billion
The company has 52.29 B in debt with debt to equity (D/E) ratio of 0.8, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.0, demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Glenn DavidZoetis Inc
2016
Douglas McCorkleRegeneron Pharmaceuticals
2007
John WesolowskiPerrigo Company Plc
2016
Clinton LewisZoetis Inc
2018
Paul NavarreAllergan Plc
Sandra BeatyZoetis Inc
2012
Cartikeya ReddyDr Reddys Laboratories
2016
Scott JamisonPerrigo Company Plc
2011
Joyce LeeZoetis Inc
2012
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
John GrayVertex Pharmaceuticals Incorpor
2019
Ian SmithVertex Pharmaceuticals Incorpor
2017
Christopher FenimoreRegeneron Pharmaceuticals
2017
Alejandro BernalZoetis Inc
2015
Robert StewartAllergan Plc
N/A
Michael AbermanRegeneron Pharmaceuticals
2015
CDavid NicholsonAllergan Plc
2015
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Karen LingAllergan Plc
2014
Marion McCourtRegeneron Pharmaceuticals
2018

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Correlation Analysis Now

   

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
few days ago
Traded for 8.62
GM   
Sold over 100 shares of
few days ago
Traded for 25.24
XOM   
Sold over 60 shares of
few days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
few days ago
Traded for 28.82
MSFT   
Sold few shares of
few days ago
Traded for 206.26
Please check Your Equity Center. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page